By Anna Rose Welch, editor, Biosimilar Development
Because negative news and opinions seem to create greater waves, I thought I would take stock of the positive news that may not have come over your desks or (more realistically) cellphones in the past few weeks.
The many benefits of single-use systems will make them an attractive choice for manufacturers as first-generation and next-generation drugs, or bio-betters, are introduced to the market. As originator drug batches get smaller and are made in single-use systems, biosimilars will follow suit.
By S. Ropka, D. Hillier, and A. Savit, Ph.D., Axinn, Veltrop & Harkrider LLP
This article provides insight into two recent developments that will impact strategic and economic considerations for biologics makers, particularly as it relates to interchangeability and how patentees and challenges may approach patent portfolios.
By Nigel Darby,GE Healthcare Life Sciences
The pharmaceutical industry’s success has become something of a double-edged sword, and our healthcare systems are burdened with the costs of lifestyle challenges. Everyday, businesses and healthcare professionals must work diligently to improve our quality of life, but pricing and access will continue to be a global battle that the industry must take note of.